Navigation Links
Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
Date:4/1/2011

BERLIN and RIDGEFIELD, Conn., April 1, 2011 /PRNewswire/ -- New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) demonstrate the antiviral activity of Boehringer Ingelheim's once-daily oral protease inhibitor, BI 201335, in both treatment-naive and -experienced patients with chronic genotype-1 (GT1) hepatitis C virus (HCV), the most challenging genotype of HCV to treat.  Results from SILEN-C1 show a sustained viral response (SVR) in 71 to 83 percent of treatment-naive patients who received BI 201335 once-daily plus the current standard-of-care (SOC) [pegylated interferon (PegIFN) and ribavirin (RBV)].

Results from SILEN-C2 show an SVR in 28 to 41 percent of treatment-experienced patients who received BI 201335 once-daily plus PegIFN and RBV.

"SILEN-C1 and 2 have shown positive Phase 2 results in a broad range of HCV patients," said Peter Piliero, M.D., executive director, Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "The current standard-of-care in HCV is not effective for enough patients. Protease inhibitors such as BI 201335 represent potential new options to improve outcomes and the possibility to shorten the duration of treatment for HCV disease."

"Boehringer Ingelheim is continuing its long heritage in virology and commitment to develop new medicines for HCV," continued Piliero. "BI 201335 is part of BI's growing HCV portfolio, which is being investigated with the goal of improving treatment and cure rates for HCV patients.  We are excited that we will commence our Phase 3 trial program with BI 201335 in the near future, based on the results of these Phase 2 studies."

(Oral abstract #60) SILEN-C1: Sustained Virologic Response (SVR) and Safety of BI 201335 Combined with Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Genotype-1 HCV InfectionIn this double-blind, randomized, placebo-controlled trial, 429 treatment-na
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Pa. , Jan. 23, 2015  MedScope ( www.medscope.org ... been nominated for a 2015 Connected World ... Emergency Response System (mPERS), that can be used anywhere, ... technology partner.  In nominating MedScope, ...
(Date:1/23/2015)...  Pete Rose, baseball,s all-time hits leader, is the new spokesperson ... Ducere Pharma has announced. "Pete,s a Hall of ... him on board with Myoflex," said Ducere Pharma Chief Executive ... who is known across all generations. The passion and intensity ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Feb. 24, 2011 Reportlinker.com announces that ... in its catalogue: Global ... http://www.reportlinker.com/p090668/Global-Biotechnology-Instrumentation-Industry.html This report ... in US$ Million by the following Product ...
... NEW YORK, Feb. 24, 2011 Reportlinker.com announces ... in its catalogue: Global ... http://www.reportlinker.com/p0397748/Global-Computer-Assisted-Surgical-CAS-Systems-Industry.html This ... Surgical (CAS) Systems in US$ Million by the ...
Cached Medicine Technology:Reportlinker Adds Global Biotechnology Instrumentation Industry 2Reportlinker Adds Global Computer Assisted Surgical (CAS) Systems Industry 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the basic ... , Purchasing an accidental death and dismemberment rider for a ... rider provides benefits if the insured dies in an accident. ... of life insurance. , AD&D is not expensive and ...
(Date:1/22/2015)... has added many trendy Champagne wedding dresses to ... the past three years. Today, the business announces a special ... the sales manager of the company, this is on the ... point can be reflected on the discounted wedding dresses from ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 EBSCO Information ... (AMA) are expanding their relationship in an effort to further ... the world. While EBSCO has long made AMA journals available ... sales agent for The JAMA Network. , Long ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... which could presumably play a major role in the development// ... down after examination of tumor tissue from 53 breast cancer ... which confirmed the findings. This new discovery could provide ... haunting women. ,Our improved understanding of cancer biology and genetic ...
... Japan Thursday announced a grant of $7 million for ... grant assistance would enable the Sardar Vallavbhai Patel Postgraduate ... facilities and effectively contribute towards dispensation of healthcare to ... embassy. , ,Notes concerning the project were signed ...
... doses of vitamins and minerals// are allowing themselves to ... researchers. , ,No one knows what adverse long ... the levels promoted by some alternative therapists and celebrities, ... middle-class professionals who turned to vitamins and minerals in ...
... elderly population may not be checked regularly for chronic ... in them. ,Researchers from Tufts-New England Medical Center, ... of the American Society of Nephrology that there remained ... for the geriatric patients with this health condition., ...
... on hopes for a new drug to treat women with //low ... more studies to be done on the Intrinsa patch made by ... effects the drug may induce, the Los Angeles Times reported. , ... to restore healthy sexual appetites to women struggling with low desire., ...
... attempted to commit suicide repeatedly can now be treated ... found to give better results than the other treatments ... findings were published in the current issue of JAMA. ... conducted a randomized controlled trial to determine whether a ...
Cached Medicine News:Health News:Vitamin Supplements - Good, The Bad And The Ugly 2Health News:Vitamin Supplements - Good, The Bad And The Ugly 3Health News:Geriatric Patients With Chronic Kidney Disease May Not Be Treated Properly 2Health News:FDA Diminish Hopes On ‘Female Viagra 2Health News:FDA Diminish Hopes On ‘Female Viagra 3Health News:Suicidal Tendencies May Be Treated With Cognitive Therapy 2
TDX Tape - sealing sheets for polypropylene plates only, 100/PK...
... steel with stove enamel coated (RAL 7035 grey) ... Front, back and side windows 6 ... Internal adjustable tempered glass shelf ... Lighting 600 lux AC ...
Remote Alpha Dock system for the DNA Engine line, allows, Alpha unit to function remotely (requires fan power supply)...
Reads single TrakMates tubes instantly, and drops decoded tube number instantly into any Windows application. System includes reader and Windows based software....
Medicine Products: